MedDataX Logo

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

NCT ID: NCT01815294

Last Updated: 2015-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to support the qualification of a replacement manufacturing site for DOXIL/CAELYX (doxorubicin HCL).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized (individuals will be assigned in a random order to study treatment sequences), open-label (identity of assigned treatment sequences will be known), single dose, 2-cycle, crossover (patients will receive both treatments in a random order) bioequivalence study of DOXIL/CAELYX (doxorubicin HCL) in patients with advanced or refractory solid malignancies (including patients with ovarian cancer). This study has an adaptive 2-stage design. Bioequivalence based on encapsulated doxorubicin will be tested at the end of Stage 1 using data from at least 24 ovarian cancer patients. An interim analysis of free doxorubicin will be performed at the end of Stage 1 using data from 42 patients of all cancer types. The study may continue into Stage 2 with additional patients of all cancer types; and final evaluation of bioequivalence for free doxorubicin will be performed at the end of Stage 2. The study will include a screening phase followed by an open-label treatment phase consisting of 2 doxorubicin treatment cycles and an end-of-treatment visit on Cycle 3, Day 1. Participants may enter an optional extension phase after 2 cycles. Safety will be monitored throughout the study. Blood samples for pharmacokinetic analysis will be obtained from all participants at specified times over 29 days after starting each study drug administration in Cycles 1 and 2 for determination of plasma concentrations of encapsulated and free doxorubicin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms Neoplasms, Ovarian Neoplasms, Breast Advanced or Refractory Solid Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A: DOXIL/CAELYX (doxorubicin)

50 mg/m2 of doxorubicin manufactured at the current site of manufacturing administered by IV infusion over 90 minutes on Day 1

Group Type EXPERIMENTAL

DOXIL/CAELYX (doxorubicin) Treatment Sequence AB

Intervention Type DRUG

Cycle 1 = Treatment A, Cycle 2 = Treatment B

DOXIL/CAELYX (doxorubicin) Treatment Sequence BA

Intervention Type DRUG

Cycle 1 = Treatment B, Cycle 2 = Treatment A

Treatment B: DOXIL/CAELYX (doxorubicin)

50 mg/m2 of doxorubicin manufactured at the new site of manufacturing (test product) administered by IV infusion over 90 minutes on Day 1

Group Type EXPERIMENTAL

DOXIL/CAELYX (doxorubicin) Treatment Sequence AB

Intervention Type DRUG

Cycle 1 = Treatment A, Cycle 2 = Treatment B

DOXIL/CAELYX (doxorubicin) Treatment Sequence BA

Intervention Type DRUG

Cycle 1 = Treatment B, Cycle 2 = Treatment A

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DOXIL/CAELYX (doxorubicin) Treatment Sequence AB

Cycle 1 = Treatment A, Cycle 2 = Treatment B

Intervention Type DRUG

DOXIL/CAELYX (doxorubicin) Treatment Sequence BA

Cycle 1 = Treatment B, Cycle 2 = Treatment A

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with advanced or refractory solid malignancies: histologically or cytologically confirmed advanced ovarian cancer failing platinum-based chemotherapy; histologically or cytologically confirmed metastatic breast cancer after failing approved life-prolonging therapies; any histologically or cytologically confirmed solid malignancy that is metastatic or unresectable, and for which standard treatment is no longer an option
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Recovered from acute toxicity of any prior treatment (exemptions: alopecia, grade-1 neuropathy)
* Prior doxorubicin (or other anthracyclines) at cumulative dose of \<=360 mg/m2 or cumulative epirubicin dose \<=720 mg/m2 (calculated using doxorubicin equivalent doses: 1 mg doxorubicin = 1 mg DOXIL/CAELYX = 0.3 mg mitoxantrone = 0.25 mg idarubicin)
* Adequate liver, bone marrow, and renal function according to protocol-defined parameters
* Left ventricular ejection fraction (LVEF) within normal limits of the institution as determined by multiple uptake gated acquisition (MUGA) or echocardiography
* Agrees to protocol-defined use of effective contraception
* Negative pregnancy test at screening (applicable to women of child bearing potential) within 7 days prior to starting treatment

Exclusion Criteria

* Positive history of known brain metastases or leptomeningeal disease (patients with brain metastases can only be enrolled if the following conditions are all met: treated and stable for \>4 weeks \[\>2 weeks after SRS/Cyberknife\]; no evidence for progression or hemorrhage after treatment; steroid treatment discontinued at least 2 weeks prior to first administration of doxorubicin; enzyme inducing anti-epileptic drugs discontinued at least 4 weeks before first administration of doxorubicin
* History of hypersensitivity reaction to doxorubicin HCl or other components of DOXIL/CAELYX
* Any major surgery, radiotherapy, or immunotherapy within the last 21 days (limited palliative radiation allowed \>=2 weeks prior to the first dose; \>=4 weeks for whole brain radiotherapy); chemotherapy regimens with delayed toxicity within the last 4 weeks (or within the last 6 weeks for prior nitrosourea or mitomycin C); chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks
* Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of doxorubicin
* Unstable angina or myocardial infarction within the preceding 12 months; congestive heart failure or any history of uncontrolled cardiac disease \>Class II based on New York Heart Association Criteria
* Has an infection that is either an uncontrolled infection, clinically important (occurred within 4 weeks prior to first dose of study agent), or requiring current systemic intravenous treatment
* Uncontrolled concurrent illness including, but not limited to, poorly controlled hypertension or diabetes, or psychiatric illness/social situation that may potentially impair patient's compliance with study procedures
* Concomitant use of strong CYP3A4 inhibitors (such as clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, nefazodone, ritonavir, telithromycin and verapamil) and strong CYP3A4 inducers (such as carbamazepine, phenobarbital, phenytoin, rifampin and St John's wort) from at least 4 weeks before the first dose of doxorubicin in Cycle 1 and until after completion of all pharmacokinetic sampling in Cycle 2
* Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments
* Woman who is pregnant, or breast-feeding, or planning to become pregnant or is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nashville, Tennessee, United States

Site Status

San Antonio, Texas, United States

Site Status

Brussels, , Belgium

Site Status

Wilrijk, , Belgium

Site Status

Barcelona, , Spain

Site Status

Madrid, , Spain

Site Status

Valencia, , Spain

Site Status

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Spain United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_7051&studyid=3629&filename=CR100961_CSR.pdf

A Pivotal Bioequivalence Study of DOXIL®/CAELYX® Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DOXILNAP1002

Identifier Type: OTHER

Identifier Source: secondary_id

2013-000376-15

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CR100961

Identifier Type: -

Identifier Source: org_study_id